Export 904 results:
Author Title [ Type(Asc)] Year
Filters: First Letter Of Last Name is F  [Clear All Filters]
Journal Article
Félix, L. M., Correia, F., Pinto, P. A., Campos, S. P., et al. (2017). Propofol affinity to mitochondrial membranes does not alter mitochondrial function. European Journal of Pharmacology, 803, 48 - 56.
Félix, L. M., Correia, F., Pinto, P. A., Campos, S. P., et al. (2017). Propofol affinity to mitochondrial membranes does not alter mitochondrial function. European Journal of Pharmacology, 803, 48 - 56.
Ferreira, M., Torraco, A., Rizza, T., Fattori, F., et al. (2011). Progressive cavitating leukoencephalopathy associated with respiratory chain complex i deficiency and a novel mutation in NDUFS1. Neurogenetics, 12(1), 9 - 17.
Ferreira, M., Torraco, A., Rizza, T., Fattori, F., et al. (2011). Progressive cavitating leukoencephalopathy associated with respiratory chain complex i deficiency and a novel mutation in NDUFS1. Neurogenetics, 12(1), 9 - 17.
Borsari, C., Lucian, R., Pozzi, C., Poehner, I., et al. (2016). Profiling of flavonol derivatives for the development of antitrypanosomatidic drugs. Journal of Medicinal Chemistry, 59(16), 7598 - 7616.
Montani, L., Buerki-Thurnherr, T., de Faria, J. P., Pereira, J. A., et al. (2014). Profilin 1 is required for peripheral nervous system myelination. Development (Cambridge), 141(7), 1553 - 1561.
Montani, L., Buerki-Thurnherr, T., de Faria, J. P., Pereira, J. A., et al. (2014). Profilin 1 is required for peripheral nervous system myelination. Development (Cambridge), 141(7), 1553 - 1561.
Montani, L., Buerki-Thurnherr, T., de Faria, J. P., Pereira, J. A., et al. (2014). Profilin 1 is required for peripheral nervous system myelination. Development (Cambridge), 141(7), 1553 - 1561.
Santos, R., Oliveira, J., Vieira, E., Coelho, T., et al. (2010). Private dysferlin exon skipping mutation (c.5492G > A) with a founder effect reveals further alternative splicing involving exons 49-51. Journal of Human Genetics, 55(8), 546 - 549.
Coimbra, S., Oliveira, H., Belo, L., Figueiredo, A., et al. (2013). Principal determinants of the length of remission of psoriasis vulgaris after topical, NB-UVB, and PUVA therapy: A follow-up study. American Journal of Clinical Dermatology, 14(1), 49 - 53.
Westermark, P., Benson, M. D., Buxbaum, J. N., Cohen, A. S., et al. (2007). A primer of amyloid nomenclature. Amyloid, 14(3), 179 - 183.
Lopes, V. R., Fernández, N., Martins, R. F., & Vasconcelos, V. (2010). Primary screening of the bioactivity of brackishwater cyanobacteria: Toxicity of crude extracts to Artemia salina larvae and Paracentrotus lividus embryos. Marine Drugs, 8(3), 471 - 482.
Pinto, R., Caseiro, C., Lemos, M., Lopes, L., et al. (2004). Prevalence of lysosomal storage diseases in Portugal. European Journal of Human Genetics, 12(2), 87 - 92.
Rocha, S., Vitorino, R. M. P., Lemos-Amado, F. M., Castro, E. B., et al. (2008). Presence of cytosolic peroxiredoxin 2 in the erythrocyte membrane of patients with hereditary spherocytosis. Blood Cells, Molecules, and Diseases, 41(1), 5 - 9.
Bastos, H. N., Osório, N. S., Castro, A. G., Ramos, A., et al. (2016). A prediction rule to stratify mortality risk of patients with pulmonary tuberculosis. PLoS ONE, 11(9).
Bastos, H. N., Osório, N. S., Castro, A. G., Ramos, A., et al. (2016). A prediction rule to stratify mortality risk of patients with pulmonary tuberculosis. PLoS ONE, 11(9).
Melo, S., Figueiredo, J., Fernandes, M. S., Gonçalves, M., et al. (2017). Predicting the functional impact of CDH1 missense mutations in hereditary diffuse gastric cancer. International Journal of Molecular Sciences, 18(12).
Melo, S., Figueiredo, J., Fernandes, M. S., Gonçalves, M., et al. (2017). Predicting the functional impact of CDH1 missense mutations in hereditary diffuse gastric cancer. International Journal of Molecular Sciences, 18(12).
Butler, J. S., Chan, A., Costelha, S., Fishman, S., et al. (2016). Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid, 23(2), 109 - 118.
Butler, J. S., Chan, A., Costelha, S., Fishman, S., et al. (2016). Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid, 23(2), 109 - 118.
Butler, J. S., Chan, A., Costelha, S., Fishman, S., et al. (2016). Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid, 23(2), 109 - 118.
Cecílio, P., Pérez-Cabezas, B., Fernandez, L., Moreno, J., et al. (2017). Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis. PLoS Neglected Tropical Diseases, 11(11).
Cecílio, P., Pérez-Cabezas, B., Fernandez, L., Moreno, J., et al. (2017). Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis. PLoS Neglected Tropical Diseases, 11(11).
Ferreira, D. A., Nunes, C. S., Antunes, L., Lobo, F., & Amorim, P. (2006). Practical aspects of the use of target controlled infusion with remifentanil in neurosurgical patients: Predicted cerebral concentrations at intubation, incision and extubation. Acta Anaesthesiologica Belgica, 57(3), 265 - 270.
Paiva-Martins, F., Fernandes, J., Santos, V., Silva, L., et al. (2010). Powerful protective role of 3,4-dihydroxyphenylethanol-elenolic acid dialdehyde against erythrocyte oxidative-Lnduced hemolysis. Journal of Agricultural and Food Chemistry, 58(1), 135 - 140.

Pages


Home | Site Map | Contacts | Credits | Privacy & Cookies | Intranet | Social Networks |


rua alfredo allen, 208, 4200-135 porto - portugal | tel +351 220 408 800 | email: info@i3s.up.pt | © copyright 2010 ibmc